17:18 EDT Apellis (APLS) Pharmaceuticals trading halted, news pending
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $50 from $47 at Baird
- Apellis price target raised to $24 from $23 at BofA
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating
- Apellis Pharmaceuticals: Sustained Growth Potential and Market Resilience Justify Buy Rating
- Apellis price target raised to $26 from $25 at Morgan Stanley